RecruitingPHASE1, PHASE2NCT06710132
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Principal Investigator
- Medical ResponsibleMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Intervention
- M9140(drug)
- Enrollment
- 250 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- University of California - Los Angeles - 300208353, Santa Monica, California, United States
- Providence Medical Foundation, Santa Rosa, California, United States
- Georgetown University - Lombardi Comprehensive Cancer Center - 1134847, Washington D.C., District of Columbia, United States
- D&H Cancer Research Center, Margate, Florida, United States
- Memorial Cancer Institute at Memorial Healthcare System, Pembroke Pines, Florida, United States
- Prisma Health Cancer Institute, ITOR, CRU, Greenville, South Carolina, United States
- Baptist Cancer Center, Memphis, Tennessee, United States
- Baptist Memorial Health Care -Memphis, Memphis, Tennessee, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- University of Texas M. D. Anderson Cancer Center - Partner, Houston, Texas, United States
- NEXT Virginia, Fairfax, Virginia, United States
- Flinders Medical Centre, Bedford Park, Australia
- Nepean Cancer Care Centre, Kingswood, Australia
- Mater Misericordiae Ltd - PARENT, South Brisbane, Australia
- Macquarie University Hospital - PARENT, Sydney, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Merck KGaA, Darmstadt, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06710132 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- ACTIVE NOT RECRUITINGNCT07448493Local Treatment Strategies for Brain Metastases of Gastric and Esophageal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGPHASE1, PHASE2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsEikon Therapeutics
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →